Temasek, Ally Bridge Group, a global healthcare-focused investment group, and TCG Crossover, a science-driven investment firm, led a $215 Series B funding round in Arbor Biotechnologies. “With this investment, we are well-positioned to continue advancing toward the clinic with our initial focus in liver and first-in-class treatments for CNS diseases, as well as continue to build out our proprietary discovery engine. While our primary focus has been on developing our bespoke CRISPR nucleases, we are also looking to progress our other precision editing innovations, such as CRISPR transposases," Devyn Smith, Arbor Biotechnologies CEO.